Mitchell Ho, of Nat. Cancer Institute to Talk at Antibody & Protein Mtg, Oct 23-24, 2014, Boston, MA

Top Quote Mitchell Ho, Chief of the Antibody Therapy Section of the National Cancer Institute to give a presentation titled, "Development of Therapeutic Antibodies Targeting Glypican-3 in Liver Cancer" at the Antibody and Protein Therapeutics Conference, October 23 & 24, 2014, in Boston, MA by GTCbio. End Quote
  • (1888PressRelease) May 20, 2014 - Mitchell Ho, Ph.D., is an Investigator at the National Cancer Institute (NCI). He is Chief of Antibody Therapy Section in the Laboratory of Molecular Biology, NCI and serves as Chair of the NIH Antibody Interest Group. Research in the Ho lab aims to understand the biology of cancer driven by cell surface glycoproteins and to develop novel antibody-based cancer therapies.

    His research team is currently studying glypican-3 and mesothelin as potential targets for cancer therapy. He has developed mammalian cell display for antibody discovery and used in vitro tumor spheroids in the field of therapeutic antibody research. Dr. Ho received his Ph.D. from the University of Illinois at Urbana Champaign and completed his postdoctoral fellowship in the laboratory of Dr. Ira Pastan at the NIH.

  • FB Icon Twitter Icon In-Icon
Contact Information